Gubra A/S
GUBRA | CO
Overview
Corporate Details
- ISIN(s):
- DK0062266474
- LEI:
- 254900T17RRFZONO6W53
- Country:
- Denmark
- Address:
- Hørsholm Kongevej 11 B, 2970 Hørsholm
- Website:
- https://www.gubra.dk/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of development milestone payments and potential royalties from the D&P business.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nykode Therapeutics ASA | Norway | NYKD | |
|
Oculis Holding AG | Switzerland | OCS | |
|
ONCODESIGN | France | ALONC | |
|
Oncodesign Precision Medicine S.A | France | ALOPM | |
|
Oncoinvent ASA | Norway | OCIN | |
|
Oncopeptides | Sweden | ONCO | |
|
Onxeo | France | ALONX | |
|
OPKO Health Inc. | Israel | OPK | |
|
Oramed Pharmaceuticals Inc. | Israel | ORMP | |
|
Oryzon Genomics S.A. | Spain | ORY |